REAKTEnvironment and Methodology for Real-time Knowledge-based Systems
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
REAKT, the follow-up project to SAFER, is currently under negotiation.
- Ness Ziona, Israel- and Chapel Hill, North Carolina-based late stage clinical biotechnology company Atox Bio has enrolled the first patient in the Phase 2 REAKT study of Reltecimod in treatment of patients with abdominal sepsis and stage 2/3 acute kidney injury (AKI), the company said.
The Phase 2 REAKT study is a randomised, placebo-controlled trial across multiple level 1 trauma centers in the US with the primary endpoint of complete recovery from stage 2/3 AKI.